



Guerbet launches a new multi-patient solution, with no compromise on efficiency and patient safety

Presented for the first time at the Radiological Society of North America meeting (RSNA, Chicago, November 25–30, 2018), this solution broadens Guerbet’s multi-patient range

Villepinte, November 23, 2018 (8:00 CET) - Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that the OptiVantage® multi-use injector is now CE-marked. This injector is designed for injecting contrast agents used in X-ray (CT scan) medical examinations.

This new solution includes the tried-and-tested OptiVantage® syringe-based injector, a complete range of associated syringes and disposables (manyFill® day set and secufill® patient line), services and support systems (OptiProtect™).

OptiVantage® multi-use will initially be marketed in EMEA from January 2019, then progressively in other regions of the world (Asia and Latin America).

Existing OptiVantage® customers may benefit from an upgrade to easily implement the new multi-use feature.

Guerbet Group Chief Commercial Officer, Diagnostic Imaging, David Hale declared: *“We are delighted to be providing radiology professionals with this new multi-use injection solution, which answers market needs without compromising efficiency and patient safety.”*

The market targeted by OptiVantage® multi-use represents over half of all CT procedures worldwide.

Press release

About OptiVantage®

Launched in 2005, the OptiVantage® injector is a medical device (Class: IIb, CE0123) intended for use by medical imaging and diagnostic health professionals, for injecting radiopaque contrast media and saline into a patient's vascular system during CT examinations. The new version is adapted to multi-use markets and is available in pedestal and ceiling-mount versions. OptiVantage® is a registered Guerbet trademark.

Refer to the product instructions for use for full information on precautions and the correct use of the medical device.

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed across its four centers in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €807 million in revenue in 2017.

For more information about Guerbet, please visit www.guerbet.com

Contacts

Guerbet

Anne-Laure Delasalle,
Communications Director
+ 33 (0)1 45 91 50 03
anne-laure.delasalle@guerbet-group.com

Media Relations

Alize RP
Caroline Carmagnol and Tatiana Vieira
+33 (0)1 44 54 36 65 / +33 (0)6 31 19 76 20
guerbet@alizerp.com